N/A
Manufactured by Hikma Pharmaceuticals USA Inc.
60,859 FDA adverse event reports analyzed
Last updated: 2026-04-15
CAFFEINE CITRATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Hikma Pharmaceuticals USA Inc.. The most commonly reported adverse reactions for CAFFEINE CITRATE include PEMPHIGUS, PERICARDITIS, HEPATIC ENZYME INCREASED, ALOPECIA, GLOSSODYNIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CAFFEINE CITRATE.
Out of 2,137 classified reports for CAFFEINE CITRATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 60,859 FDA FAERS reports that mention CAFFEINE CITRATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include PEMPHIGUS, PERICARDITIS, HEPATIC ENZYME INCREASED, ALOPECIA, GLOSSODYNIA, PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Hikma Pharmaceuticals USA Inc. in connection with CAFFEINE CITRATE. Always verify the specific product and NDC with your pharmacist.